Delving into the Latest Updates on Schering Deutschland Gmbh with Synapse

概览

疾病领域	数量

神经系统疾病	1

排名前五的药物类型	数量

小分子化药	1
造影剂	1

排名前五的靶点	数量

M1 receptor x M3 receptor	1

关联

1

项与 Schering Deutschland Gmbh 相关的药物

Iopromide

碘普罗胺

靶点

M1 receptor x M3 receptor

作用机制

M1 receptor拮抗剂 [+2]

在研机构

Bayer HealthCare Pharmaceuticals, Inc. [+4]

原研机构-

在研适应症

乳腺疾病 [+6]

非在研适应症

诊断试剂

最高研发阶段批准上市

首次获批国家/地区

澳大利亚

首次获批日期1991-09-12

100 项与 Schering Deutschland Gmbh 相关的临床结果

登录后查看更多信息

0 项与 Schering Deutschland Gmbh 相关的专利（医药）

登录后查看更多信息

7

项与 Schering Deutschland Gmbh 相关的文献（医药）

2007-04-01·Multiple Sclerosis Journal2区 · 医学

The Faces Symbol Test, a newly developed screening instrument to assess cognitive decline related to multiple sclerosis: first results of the Berlin Multi-Centre FST Validation Study

2区 · 医学

Article

作者: Schulz, I. ; Nippert, I. ; Scherer, P. ; Benesch, G. ; Behringer, A. ; Finke, G. ; Zimmermann, M. ; Plenio, A. ; Hauser, R. ; Rohr, A. ; Anvari, K. ; Burger-Deinerth, E. ; Ringel, I. ; Tiel-Wilck, K. ; Peglau, I. ; Hilbert, K. ; Boldt, H. ; Wilke-Burger, H. ; Kaskel, P. ; Isakowitsch, K. ; Reischies, F. ; Zahrnt, S. ; Ehret, R. ; Penner, I.K. ; Friedrich, H. ; Breitkopf, S. ; Kugler, J. ; Bergtholdt, B.

Reliable, language-independent, short screening instruments to test for cognitive function in patients with multiple sclerosis (MS) remain rare, despite the high number of patients affected by cognitive decline. We developed a new, short screening instrument, the Faces Symbol Test (FST), and compared its diagnostic test characteristics with a composite of the Digit Symbol Substitution Test (DSST) and the Paced Auditory Serial Addition Test (PASAT), in 108 MS patients and 33 healthy controls. An Informant-Report Questionnaire, a Self-Report Questionnaire, and a neurologist's estimation of the Every Day Life Cognitive Status were also applied to the MS patients. The statistical analyses comprised of a receiver operating characteristic analysis for test accuracy and for confounding variables. The PASAT and DSST composite score estimated that 36.5% of the MS patients had cognitive impairment. The FST estimated that 40.7% of the MS patients were cognitively impaired (sensitivity 84%; specificity 85%). The FST, DSST and PASAT results were significantly correlated with the patients' physical impairment, as measured by the Expanded Disability Status Scale (EDSS). The results suggest that the FST might be a culture-free, sensitive, and practical short screening instrument for the detection of cognitive decline in patients with MS, including those in the early stages. Multiple Sclerosis 2007; 13: 402-411. http://msj.sagepub.com.libproxy1.nus.edu.sg

2006-07-01·Radiation and Environmental Biophysics4区 · 环境科学与生态学

The effect of the β-emitting yttrium-90 citrate on the dose–response of dicentric chromosomes in human lymphocytes: a basis for biological dosimetry after radiosynoviorthesis

4区 · 环境科学与生态学

Article

作者: H.-J. Selbach ; F. J. Gildehaus ; J. Pinkert ; E. Schmid ; M. Haney ; R. Klett ; M. Voth

The production of dicentric chromosomes in human lymphocytes by beta-particles of yttrium-90 (Y-90) was studied in vitro to provide a basis of biological dosimetry after radiosynoviorthesis (RSO) of persistent synovitis by intra-articular administration of yttrium-90 citrate colloid. Since the injected colloid may leak into the lymphatic drainage exposing other parts of the body to radiation, the measurement of biological damage induced by beta-particles of Y-90 is important for the assessment of radiation risk to the patients. A linear dose-response relationship (alpha = 0.0229 +/- 0.0028 dicentric chromosomes per cell per gray) was found over the dose range of 0.2176-2.176 Gy. The absorbed doses were calculated for exposure of blood samples to Y-90 activities from 40 to 400 kBq using both Monte Carlo simulation and an analytical model. The maximum low-dose RBE, the RBE(M) which is equivalent to the ratio of the alpha coefficients of the dose-response curves, is well in line with published results obtained earlier for irradiation of blood of the same donor with heavily filtered 220 kV X-rays (3.35 mm copper), but half of the RBE(M) relative to weakly filtered 220 kV X-rays. Therefore, it can be concluded that for estimating an absorbed dose during RSO by the technique of biological dosimetry, in vitro and in vivo data for the same radiation quality are necessary.

2006-01-01·Journal of Neural Transmission4区 · 医学

Lisuride treatment of Restless Legs Syndrome: first studies with monotherapy in de novo patients and in combination with levodopa in advanced disease

4区 · 医学

Article

作者: A. Rodenbeck ; A. Deissler ; R. Kohnen ; A. Engfer ; H. Beneš

In two 4-week polysomnography pilot studies with 10 patients each, we investigated the efficacy of oral lisuride as monotherapy in de novo RLS patients as well as in combination with levodopa in advanced RLS. Daily doses at study end were 0.3 mg lisuride, plus 150 mg levodopa in the combination study. Marked improvements occurred in both studies in different PLM indexes and in the CGI. Levodopa dose could be decreased by 27%. Lisuride might be an efficacious treatment for RLS in general, and in combination with levodopa in advanced stage.

100 项与 Schering Deutschland Gmbh 相关的药物交易

登录后查看更多信息

100 项与 Schering Deutschland Gmbh 相关的转化医学

登录后查看更多信息